Inmed announces results of 2023 annual general meeting

Vancouver, british columbia--(newsfile corp. - december 19, 2023) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual general meeting of shareholders held on december 19, 2023 (the "meeting"), all of the matters put forward before shareholders for consideration and approval as set out in inmed's notice of meeting and management information circular, dated october 27, 2023, were approved by the shareholders. a total of 1,292,647 common shares of the company, representing approximately 38.84% of the company's 3,328,191 issued and outstanding common shares, were represented in person or by proxy at the meeting.
INM Ratings Summary
INM Quant Ranking